A German-rooted biotech focused on mental health has closed a significant funding round aimed at advancing treatments for one of the world's most common — and still inadequately treated — conditions.
HMNC Brain Health has raised $50 million in a Series B financing round, according to Endpoints News. The round was led by Medice, a family-owned German drugmaker, and backed by additional investors. The capital is earmarked to push two psychiatry programs into mid-stage clinical studies.
Depression affects hundreds of millions of people globally, yet a large share of patients don't respond adequately to existing antidepressants. The pipeline for genuinely new mechanisms of action remains thin, which makes any serious investment in novel depression treatments notable.
HMNC, which stands for precision psychiatry rooted in biological and neurological understanding, is betting that a more targeted approach to brain health can crack problems that decades of blunt-instrument antidepressants have not. Mid-stage trials — typically Phase 2 studies — are where drugs begin to demonstrate whether they actually work in patients, making this a pivotal moment for both programs.
The lead from Medice, a privately held German company with deep roots in neurology and psychiatry, signals a strategic alignment between an established pharmaceutical player and a biotech looking to move quickly through the clinical pipeline.
If even one of these two programs succeeds in mid-stage testing, it could open a path toward a new class of depression treatment — a field where patients, clinicians, and investors have been waiting a long time for a breakthrough.